NCT00128167已完成3 期
A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6-59 Months of Age
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 8,500
- 试验地点
- 301
- 主要终点
- influenza surveillance period and at least 14 days after the last required vaccination
研究概览
简要总结
The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 6 Months 至 59 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 6-59 months of age (not yet reached their 5th birthday)
- •Parent or guardian available by telephone
- •Available for illness visits at clinic or at home during the influenza surveillance period
- •Written informed consent (and Health Insurance Portability and Accountability Act [HIPAA] authorization for U.S. Participants) obtained from the participant's parent or legal guardian and
- •Ability of the parent/guardian to understand and comply with the requirements of the protocol
排除标准
- •History of hypersensitivity to any component of CAIV-T or inactivated influenza vaccine, including egg or egg protein
- •History of hypersensitivity to gentamicin
- •Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy
- •History of Guillain-Barre syndrome
- •Medically-diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled) within the previous 42 days by parent report or chart review (e.g., children with recent persistent asthma are excluded), or history of severe asthma
- •Acute febrile (>100.0 degrees F or >37.8 degrees C oral or equivalent) illness or acute respiratory illness, including sore throat, within three days prior to enrollment
- •Receipt of an investigational product within 30 days prior to enrollment or expected receipt during this study
- •Use of aspirin or salicylate-containing products 30 days prior to enrollment or expected receipt during this study
- •Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within 14 days prior to enrollment or expected receipt during this study
- •Receipt of any blood product within 90 days prior to vaccination or expected receipt during this study
- •Administration of any live virus vaccine within 30 days prior to enrollment, or if receipt of another live virus vaccine is expected within 30 days of any study vaccination
- •Administration of any inactivated vaccine within 14 days prior to enrollment or if receipt of another inactivated vaccine is expected within 14 days prior to enrollment or if receipt of another inactivated vaccine is expected within 14 days of any study vaccination
- •Close contact who is severely immunocompromised (e.g., transplant recipient)
- •Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study and
- •Any condition that, in the opinion of the investigator, might interfere with the interpretation or evaluation of the vaccines.
结局指标
主要结局
influenza surveillance period and at least 14 days after the last required vaccination
The primary efficacy endpoint of this study is the relative efficacy of CAIV-T
compared to TIV against the incidence of culture-confirmed symptomatic influenza infection caused by community-acquired wild-type strains antigenically similar to those contained in the vaccine, occurring during the
次要结局
- Febrile acute otitis media (AOM) with antibiotic use associated with culture-confirmed influenza infection regardless of antigenic match
- Culture-confirmed symptomatic influenza infection regardless of antigenic match
- Febrile acute otitis media (AOM) with antibiotic use associated with culture-confirmed influenza infection antigenically similar to vaccine strains
- Lower respiratory illness (LRI) with culture-confirmed influenza infection antigenically similar to vaccine strains and
- Lower respiratory illness (LRI) with culture-confirmed influenza infection regardless of antigenic match
研究者
研究点 (301)
Loading locations...
相似试验
已完成
3 期
MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)Type 2 Diabetes MellitusNCT00482729Merck Sharp & Dohme LLC1,246
已完成
3 期
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With HypertensionHypertensionNCT02235909Arbor Pharmaceuticals, Inc.377
已完成
2 期
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile InfectionClostridioides Difficile InfectionNCT04781387Crestone, Inc43
已完成
3 期
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal OsteoporosisOsteoporosisMenopauseNCT00808132Pfizer1,886
终止
不适用
Moderato System: A Double-Blind Randomized Trial Ver 1.1Hypertension Resistant to Conventional TherapyBradycardiaAtrioventricular BlockNCT02837445BackBeat Medical Inc70